Bausch Health Companies Inc Stock Price, News & Analysis

Bausch Health Companies Inc. (BHC) announced the launch of LiverHEalthNow, an online resource aimed at improving the detection and management of Overt Hepatic Encephalopathy (OHE) in chronic liver disease patients. This initiative coincides with Liver Awareness Month and aims to educate healthcare providers and patients. Approximately 30 million Americans are affected by liver disease, with OHE being a severe complication. Salix Pharmaceuticals, part of Bausch Health, emphasizes the importance of early detection to improve patient outcomes and reduce hospital readmissions.

Bausch Health's LUMIFY® Eye Drops Honored in Nielsen's 2020 Top 25 Breakthrough Innovations

On October 1, 2020, Bausch Health Companies Inc. (BHC) announced that its LUMIFY redness reliever eye drops were recognized in the "Superstar" category by BASES, a Nielsen Global Consumer division, for outstanding sales and market growth. Launched in 2018, LUMIFY has secured a 40% market share among redness relievers and is the top recommended brand by eye doctors. This accolade highlights LUMIFY's effectiveness and innovative marketing, driving significant category growth and consumer engagement.

Bausch Health Companies Inc. announced that its ophthalmic solution, VYZULTA (latanoprostene bunod), has received regulatory approval in Ukraine, increasing its market reach to seven countries including the United States and Canada. In Canada, VYZULTA is now publicly reimbursed in multiple provinces. Moreover, Medicare Part D coverage in the U.S. rose to approximately 45% from 30%. The treatment is aimed at reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company aims to secure more approvals globally.

Bausch Health Companies released its 2019 Corporate Social Responsibility (CSR) Report, emphasizing its commitment to ethical and sustainable business practices. The report discusses the company's initiatives in five key areas: integrity, environmental respect, global health, community improvement, and employee well-being. Significant highlights include reductions in energy and carbon emissions, established an Energy Efficiency Group, and continued responsible pricing strategies with average annual price increases capped at single digits. The company also outlines its response to COVID-19 and ongoing diversity and inclusion efforts.

Bausch Health Companies Inc. (BHC) has resolved intellectual property disputes with Sun Pharmaceutical regarding XIFAXAN® (rifaximin) 200 mg and 550 mg tablets, maintaining market exclusivity until 2028. Under the agreement, Sun will receive a non-exclusive license to market generic versions effective January 1, 2028, pending FDA approval. The litigation will be dismissed, and all intellectual property for XIFAXAN remains intact, with 26 patents securing its market position. Final patent expirations are set for July and October 2029.

Bausch Health has announced an agreement to acquire an option to purchase all ophthalmology assets from Allegro Ophthalmics, including global rights to risuteganib, an investigational treatment for dry age-related macular degeneration (AMD). The acquisition is valued at $50 million, with a $10 million initial payment and a contingent $40 million payment expected in 2021. Risuteganib targets multiple pathways involved in AMD, addressing a significant unmet medical need affecting millions globally. The acquisition aligns with Bausch Health's strategy to enhance its pipeline in eye health.

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced a presentation by CEO Joseph C. Papa and CFO Paul S. Herendeen at the virtual 18th Annual Morgan Stanley Global Healthcare Conference on Sept. 16, 2020, at 1:15 p.m. ET. The presentation focuses on the company's business recovery post-COVID-19 and updates on its plan to spin off the eye health business. The presentation details are available on Bausch Health's Investor Relations page. Bausch Health aims to enhance global health through its pharmaceutical and medical products.

The Bausch Foundation, overseen by Bausch Health (BHC), released its inaugural activity report detailing philanthropy initiatives from late 2017 to June 30, 2020. The Foundation aims to enhance patient lives globally by providing access to essential medicines and supporting healthcare education. Notably, Bausch Health donated approximately $600 million in pharmaceutical products in 2018 and 2019 to aid financially struggling patients. The Foundation focuses on disease prevention, improving patient outcomes, education, and global relief efforts.

Bausch Health Companies will participate in the 18th Annual Morgan Stanley Global Healthcare Conference on Sept. 16, 2020, at 1:15 p.m. ET. Key executives, including Joseph C. Papa (Chairman and CEO), Sam Eldessouky (SVP), and Arthur J. Shannon (SVP of Investor Relations), will present. Investors can access a live webcast and audio archive on the company’s Investor Relations page. Bausch Health focuses on pharmaceuticals, medical devices, and over-the-counter products, particularly in eye health, gastroenterology, and dermatology.